Background: Although systemic corticosteroid (SCS) treatment, irrespective of dura-
| INTRODUCTION
Frequent short-or long-term corticosteroid use is associated with substantial adverse effects, including osteoporosis, peptic ulcers, cataracts, adrenal suppression, weight gain, hyperglycemia, hypertension, mood problems, and diabetes. [1] [2] [3] [4] For example, Iribarren et al 2 reported the risks of coronary heart disease and all-cause mortality increased 2.5-and 2.6-fold, respectively, for patients with asthma compared with matched controls. This was driven by asthmaassociated oral corticosteroid (OCS) use. In addition, the increased risk of adverse effects is dependent on corticosteroid dosage.
2,5-8
Dalal et al 8 found that long-term corticosteroid users (≥6 months) with low-(<5 mg/day), medium-(≥5-10 mg/day), and high-dosage (>10 mg/day) exposure had, respectively, a 2.5-, 2.95-, and 3.32-fold greater adjusted relative risk of developing any steroid-related complication compared with steroid nonusers.
However, all previous studies had a relatively short baseline period that prevented true identification of systemic corticosteroid (SCS) initiators and, consequently, the study of longitudinal effects of SCS use from its initiation on adverse outcomes. [1] [2] [3] [4] [5] [6] [7] [8] Furthermore, the longest follow-up period in previous studies was only up to 4 years, prohibiting the study of long-term impact of corticosteroid use on adverse outcomes. There are limited data available on the longitudinal impact of SCS exposure on healthcare systems, although the effect of SCS use on short-term healthcare resource utilization (HCRU) and associated costs has begun to be reported in the literature. 8, 9 In an analysis of adverse drug events (ADEs) in hospitals,
Weiss and colleagues 9 found corticosteroid use to be among the top three causes of ADEs associated with hospital admission in the United States. Using a commercial database in the United States, Dalal et al 8 found adjusted annual, incremental, steroid-related complication costs of $2670, $4639, and $9162 (2014 US $) over a 1.5-year median follow-up period for long-term low-, medium-, and high-dosage steroid users, respectively, compared with nonusers.
In this study, we compared the long-term incremental risks of adverse outcomes and their associated HCRU and costs for patients with asthma who did and did not initiate SCS (parenteral corticosteroid or OCS) and who had complete primary and secondary HCRU data.
Furthermore, we explored how healthcare costs changed over time.
| METHODS
Additional details regarding the methods for cost estimations, measures and definitions, and statistical analyses are contained in the Appendices A-D, Tables S1-S6.
| Data source
We conducted a matched, historical cohort study using data from using the Clinical Practice Research Datalink (CPRD) database. The CPRD contains longitudinal data from 5 million active medical records from more than 600 subscribing practices throughout the United Kingdom. The CPRD data set contains patient records from June 1994 through January 2015, with 39% of patient data linked to Hospital Episode Statistics (HES), a data warehouse containing
G R A P H I C A L A B S T R A C T
A greater cumulative incidence of adverse outcomes is correlated with greater systemic corticosteroid dosage for patients with asthma.
Patients with asthma receiving systemic corticosteroids experience increases in annual health care resource utilization and costs, while those not receiving systemic corticosteroids do not. A dose-dependent increase in all-cause adverse outcome (excluding asthma)-associated annual health care resource utilization and costs occurs for patients with asthma receiving systemic corticosteroids.
complete and reliable information on inpatient hospital admissions, with linkage available from April 1997 through February 2016.
10
CPRD also includes information from general practice (GP) visits.
Public health researchers have used CPRD, formerly known as the General Practice Research Database, since 1987. 11 This study involved anonymized patient data that did not require ethics board approval, and was approved by the CPRD Independent Scientific Advisory Committee (reference number 17_002).
| Study design and patients
The study used a minimum 1-year baseline period and a minimum 2--year outcome (follow-up) period. The index date was the date of the first recorded prescription for a parenteral corticosteroid or OCS in the SCS arm, whereas for the non-SCS arm, it was the nearest GP visit to the matched-case index date. We matched non-SCS patients to SCS dosages were standardized into prednisolone equivalents (Table S3) .
To account for all HCRU outcomes, we included only the subset of unbroken matched pairs of active asthma patients with HES linkage in the final study population. 10 We followed patients in both arms from the index date to the end of follow-up (ie, death, leaving the primary care practice, end of available records, or last date of extraction).
Patients in the SCS arm were ≥18 years old at first SCS prescription and had ≥1 SCS prescription within 18 months after first SCS prescription. Patients could not have a diagnosis of adrenal insufficiency/Addison's disease at any time, diagnosis of cancer 5 years before or 3 months after index date, or tamoxifen prescriptions for breast cancer at any time.
To evaluate the impact of SCS on the onset of an individual adverse outcome of interest, we removed patients having the individual adverse outcome of interest before the index date. Then, we removed patients who were left without a paired counterpart.
As such, the analysis samples for the different SCS-related risk cohorts were dissimilar. Adverse outcomes evaluated are listed in Table S4 .
Given that asthma-related costs are highly driven by disease severity
and not necessarily by SCS-associated adverse outcomes, we reported HCRU and costs associated with all-cause (Table S5 ) adverse outcomes excluding asthma and those associated with asthma (defined as reported with an asthma or lower respiratory disease code) separately.
Inclusion of asthma-related costs in all-cause adverse outcome-associated costs would make the data very difficult to interpret.
| Statistical analyses
HCRU and associated costs were assessed annually, and annual averages for the entire follow-up period were calculated. We estimated HCRU-associated all-cause and cause-specific costs (2016 £) by multiplying HCRU outcomes by the estimated unit costs associated with each HCRU outcome from the Personal Social Services
Research Unit, 12 National Health Service reference costs, 13 and the Dictionary of Medicines and Devices browser. 14 Prescription cost was obtained by multiplying cost by amount prescribed. Annualized HCRU and healthcare costs were reported.
We used generalized estimating equations with cluster-robust standard errors, log link, and gamma distribution to estimate the effect of SCS initiation on annualized HCRU or costs found by bootstrapping using 1000 random samples taken, with replacement, and adjusted for potential confounders. Besides reporting on adjusted mean, we also compared SCS and non-SCS patients using incidence rate ratio (IRR) for resources and cost ratios for cost with a 95% CI.
Age and sex were used as forced covariates, and the remaining covariates were selected based on their incremental bias potential.
| RESULTS
Of 24 117 matched pairs of asthma patients, 16 623 pairs came from the CPRD database. Of these, the patients with an HES linkage were selected, and the ones who lost their matched pair were removed, resulting in 9413 total matched pairs that were included in all analyses of this study. 
| Cumulative incidence of adverse outcomes
To assess the occurrence of adverse outcomes associated with SCS exposure, we examined cumulative incidence among patients who had no recorded history of that specific outcome at baseline. Regardless of SCS dosage, 15-year cumulative incidence was higher in the SCS arm than in the non-SCS arm (eg, renal impairment: 27.9% vs 12.5%; type 2 diabetes: 9.5% vs 5.6%, respectively; Figure S1 ). Other adverse outcomes followed a similar trend. The 15-year cumulative incidences in the SCS vs non-SCS arm, respectively, were as follows:
pneumonia, 11.3% vs 3.5%; cataracts, 11.0% vs 4.4%; cerebrovascular accident, 10.0% vs 5.1%; cardio-cerebrovascular disease, 9.9% vs 3.6%; osteoporosis, 8.0% vs 2.0%; myocardial infarction, 7.3% vs 2.8%; heart failure, 3.6% vs 1.1%; and glaucoma, 3.4% vs 1.7%.
Greater SCS dosages were also correlated with greater cumulative incidence. For example, for type 2 diabetes, SCS patients with an average daily dosage of ≥7.5 mg had a 15-year cumulative incidence of 37.5%, which was 1.5-5 times greater than that of patients receiving <0.5 mg/day (cumulative incidence, 7.0%), 0.5-<2.5 mg/day (11.3%), 2.5-<5.0 mg/day (16.3%), and 5.0-<7.5 mg/day (25.0%) (Figure S2 ). For patients with an average exposure of 2.5-5 mg/day, which corresponds to three steroid bursts per year, in a 5-, 10-, and 15-year period, 5%, 10%, and 16% of these patients would develop type 2 diabetes, respectively (Table S7 ). Similar trends were observed for all other adverse outcomes (data not shown).
| Healthcare resource utilization
SCS-initiated patients with asthma had substantially greater frequency of all-cause adverse outcome-associated (excluding asthma-related) HCRU and asthma-related HCRU than patients without SCS initiation ( Table 2 ). The adjusted IRRs (95% CI) shown in Figure 1A for SCS initiation vs non-SCS were 1. (Table 2 ).
| Healthcare resource utilization-associated costs
All-cause (excluding asthma) costs associated with adverse outcomes remained constant over the follow-up period in the non-SCS arm, but these costs increased over time in the SCS arm ( Figure S3 ).
Incremental all-cause adverse outcome-associated yearly costs for SCS patients were 7% greater in the first year and 50%, 70%, and 110% greater by Years 5, 10, and 15, respectively. Similar patterns were observed for asthma-related costs, although they were not as striking ( Figure S3 ). When SCS use was categorized by mean average daily exposure (eg, >0-<0.5 mg), similar all-cause adverse outcomeassociated and asthma-related costs patterns to the overall SCS patients were observed (data not shown). Hospitalization and prescriptions were the largest contributors to HCRU differences; cost ratio (95% CI) was 4.92 (2.70-8.97) for hospitalization and 8.12 (3.93-16.75) for prescriptions in the SCS arm exposed to an average daily dosage of ≥15 mg (all P-values <0.001) ( Figure 2B ). We observed doubling of non-SCS arm annual risk outcome-associated costs in the SCS arm starting at 2.5 mg/day (Table 3, Figure 3 ). Patients who were exposed to ≥7.5 mg/day SCS had a £3226 annual cost of adverse outcomes and a £1188 annual cost of asthma, which combined was 3.3 times greater than for non-SCS patients.
We found that when compared with patients who were exposed predominantly to acute SCS dosages (those in the lowest quartile of Thus, maintenance SCS use seems to be associated with greater costs compared with acute SCS use (data not shown).
| DISCUSSION
In this report, we present the longitudinal effects of SCS treatment, irrespective of duration or dosage, on adverse outcomes, HCRU, and healthcare costs. This study was distinct from previous studies in terms of the availability of data prior to index date (50% with ≥8 years of data), allowing for a more accurate assessment of baseline SCS use and therefore identification of SCS initiators, and the long duration of its follow-up period. We found a dose-dependent increase in adverse outcomes, HCRU, and healthcare costs associated with SCS usage. To the best of our knowledge, this is the first study to report the long-term ramifications of SCS usage, both acute and long-term, on these parameters and to present these results as a function of SCS dosage.
Patients with severe, uncontrolled asthma are more likely to use OCS frequently than patients with moderate disease. 16, 17 Approximately 30%-40% of patients with severe asthma regularly use OCS to control their disease (intermittently or long term). [16] [17] [18] [19] [20] Prior Excluding asthma. Error bars represent 95% confidence interval. For adjustment, age and sex were used as forced covariates, with BMI, smoking status, antibiotic-treated infections, airflow limitation, asthma medication used (general and specified), intensive care unit stay, mechanical ventilation usage, and diagnosis of and/or treatment for diseases (Table S6) 95% confidence interval. For adjustment, age and sex were used as forced covariates, with BMI, smoking status, antibiotic-treated infections, airflow limitation, asthma medication used (general and specified), intensive care unit stay, mechanical ventilation usage, and diagnosis of and/or treatment for diseases (Table S6) All-cause adverse outcome-associated costs (excluding asthma-related costs) and an average of 7.7 years in the non-SCS arm. The average age of our study patient population was 46 years, consistent with other asthma study patient populations. 6, 10, 18 Our study is the first to demonstrate that the costs associated with SCS-associated adverse outcomes increased over the years according to SCS exposure, both overall and by SCS dosage. Incremental yearly costs for SCS patients were 7% greater in the first year and 1.5, 1.7, and 2.2 times greater by Years 5, 10, and 15,
respectively. This is consistent with incremental cumulative incidence of the adverse outcomes in the SCS arm. Even though we also observed slight increases in the adverse outcome cumulative incidence in the non-SCS arm, their longitudinal annual costs remained flat, hinting potentially that the adverse outcomes observed in the SCS arm could be more severe.
A UK study comparing nonasthma control (no exposure) with
GINA
Step 2/3 patients (low exposure) and GINA Step 5 patients (high exposure) estimated the annual cost (2013 values) of corticosteroid-induced morbidity was £224 for low-exposed group and £1310 for high-exposed group. 25 It is unclear what the dosages were in a study by Berry et al. 25 In our study, we observed a £44.70, £445.34, £1262.82, £1951.89, £1878.60, and £3283.70 incremental SCS adverse outcome-associated average annual cost for SCS exposure of 0.5-<2.5 mg/day, 2.5-<5.0 mg/day, 5.0-<7.5 mg/day, 7.5-<15.0 mg/day, and ≥15.0 mg/day, respectively.
| Limitations
This study has several limitations. Although confounding by all measured patient characteristics was considered and addressed, as in all observational research, we cannot exclude confounding by characteristics we did not measure. As patients receiving SCS may be more likely to be screened for comorbidities, an overestimation of comorbidities in this group relative to the non-SCS group may have occurred.
When looking at the different resource types, we observed a low frequency of specialist consultations and A&E attendance. In the UK healthcare system, chronic diseases are typically managed under primary care, and there is a clear tendency toward keeping as much health care as possible at the primary care level. Therefore, our HCRU results underestimated the burden that may be carried under secondary or specialist care, where we could observe much greater HCRU-associated costs. This analysis excluded those who died due to the adverse outcomes prior to the 15-year mark and most likely underestimated incidence in the SCS arm more than in the non-SCS arm.
For calculating costs for HCRU, we considered just the most prevalent SCS-related adverse outcomes rather than all possibilities.
Weight gain was identified as one of the key adverse outcomes for SCS exposure. However, we could not link weight gain to any specific HCRU-related outcomes to account for the cost. Therefore, an inability to account for adverse health effects such as weight gain led to the underestimation of the SCS burden.
We have considered a large set of covariates as potential confounders in the models. However, it is possible that information on confounding factors was not available to use. The data we used were registered during regular care, and not for research purposes.
As a result, disease history and onset could have been recorded incorrectly or not at all. These input-related variations could have led to over-or underestimation of the observed associations.
| CONCLUSIONS
Our study is the first long-term follow-up study to examine SCS adverse outcome burden and document the longitudinal detrimental effect of SCS exposure among SCS initiators. We observed an increase in cumulative incidence of adverse outcomes and associated healthcare costs over time for SCS-exposed patients. A positive dosage-response relationship was observed between average daily SCS exposure and cumulative SCS adverse outcomes incidence, associated HCRU, and healthcare costs. Even low-grade exposure to SCS was related to long-term detrimental effects of adverse outcomes.
